Search
Anastrozole
go.drugbank.com/drugs/DB01217ApprovedInvestigationalAnastrozole is a non-steroidal aromatase inhibitor (AI), similar to [letrozole], used to decrease circulating estrogen levels in the treatment of postmenopausal women with estrogen-responsive breast cancer … [A186877,A186955] Anastrozole was first approved for use in the United States in 1995.[L8863]
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesSynonyms: α,α,α',α'-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrileSofosbuvir
go.drugbank.com/drugs/DB08934ApprovedInvestigationalAs a prodrug nucleotide analog, Sofosbuvir is metabolized into its active form as the antiviral agent 2'-deoxy-2'-α-fluoro-β-C-methyluridine-5'-triphosphate (also known as GS-461203), which acts as a defective … Approved in October 2014 by the FDA, Harvoni is indicated for the treatment of HCV genotypes 1, 4, 5, and 6 with or without [DB00811] depending on the level of liver damage or cirrhosis [FDA Label].
Mixtures: VOSEVİ 400 MG/ 100 MG/ 100 MG FİLM KAPLI TABLET, 28 ADET, HARVONI 90 MG/400 MG FILM KAPLI TABLET, 28 ADETCategories: P-glycoprotein substrates, Treatments for Hepatitis CEbastine
go.drugbank.com/drugs/DB11742ApprovedInvestigationalWithdrawnEbastine is under investigation for the treatment of Irritable Bowel Syndrome (IBS). Ebastine has been investigated for the treatment of Urticaria.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: PINAVALT® 10 MG TABLETASRECUBIERTAS, EBAFIT 20 MG FILM KAPLI TABLET, 20 ADETPerindopril
go.drugbank.com/drugs/DB00790ApprovedInvestigationalIt is rapidly metabolized in the liver to perindoprilat, its active metabolite, following oral administration. … Perindoprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII).
Mixtures: Viacoram 7 mg/5 mg Tabletten, Triveram 20 mg/5 mg/5 mg FilmtablettenCategories: Heterocyclic Compounds, 2-Ring, Agents Acting on the Renin-Angiotensin SystemPyridostigmine
go.drugbank.com/drugs/DB00545ApprovedInvestigational[A231009, A231014, L32413, L32418] Pyridostigmine was granted initial FDA approval on April 6, 1955, as an oral tablet. … Myasthenia gravis is an autoimmune disease involving dysfunction at the neuromuscular junction, most commonly due to autoantibodies directed against the acetylcholine receptor (AChR), which results in
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersInternational brands: Kalymin NCobimetinib
go.drugbank.com/drugs/DB05239ApprovedInvestigationalCobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction … It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or metastatic BRAF V600 mutation-positive melanoma.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexProducts: COTELLIC® (COBIMETINIB) 20 MG TABLETAS RECUBIERTAS, COTELLIC FILM-COATED TABLET 20 MGApremilast
go.drugbank.com/drugs/DB05676ApprovedInvestigational[L7501] In July 2019, apremilast was granted a new FDA approval for the treatment of oral ulcers associated with Behcet's disease, an autoimmune condition that causes recurrent skin, blood vessel, and … Apremilast, also known as Otezla, is a phosphodiesterase 4 (PDE4) inhibitor used to treat various types of symptoms resulting from certain inflammatory autoimmune diseases.
Mixtures: OTEZLA 10 MG. 20 MG Y 30 MG, OTEZLA 10 MG. 20 MG Y 30 MGCategories: Cytochrome P-450 Substrates, P-glycoprotein substratesAlfuzosin
go.drugbank.com/drugs/DB00346ApprovedThe prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over 70. … [A228483] Alfuzosin is an alpha-1 adrenergic blocker used in the symptomatic treatment of BPH that works by relaxing the muscles in the prostate and bladder neck.
Categories: Heterocyclic Compounds, 2-Ring, Drugs Used in Benign Prostatic HypertrophySynonyms: (±)-N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furamide, N-[3-[(4-amino-6,7-dimethoxy-quinazolin-2-yl)- methyl-amino]propyl] tetrahydrofuran- 2-carboxamideOlodaterol
go.drugbank.com/drugs/DB09080ApprovedInvestigationalSingle doses of olodaterol have been shown to improve forced expiratory volume in 1 sec (FEV1) for 24 h in patients with COPD, allowing once daily dosing. … Activation of the receptor stimulates an associated G protein which then activates adenylate cyclase, catalyzing the formation of cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA).
Mixtures: SPIOLTO RESPIMAT 2.5 MCG/2.5 MCG INHALASYON ÇÖZELTISI,1 ADET, SPIOLTO®RESPIMAT®Categories: Adrenergic beta-2 Receptor Agonists, Heterocyclic Compounds, 2-RingIodixanol
go.drugbank.com/drugs/DB01249ApprovedIodixanol is a nonionic hydrophilic compound commonly used as a contrast agent during coronary angiography, particularly in individuals with renal dysfunction, as it is believed to be less toxic to the
Mixtures: BL-C KitCategories: Compounds used in a research, industrial, or household setting, X-Ray Contrast Activity